CLEO Diagnostics Takes Ovarian Cancer Test from Lab to Commercialisation Phase, Says OCRF

A more accurate test for ovarian cancer is now being taken from the lab bench into clinical use by Australian company Cleo Diagnostics (ASX:COV), according to the Ovarian Cancer Research Foundation (OCRF).

An article from OCRF revealed that the first phase of commercialisation began on August 22, 2023, and focuses on the production of an improved, more accurate diagnostic test for ovarian cancer.

The surgical triage test was funded by the OCRF, developed at the Hudson Institute of Medical Research led by Professor Andrew Stephens and is being commercialised by Cleo Diagnostics.

“This new test will help ensure that an optimal management plan can be put in place early, which will streamline the referral process and provide the best care for patients,” said Cleo Diagnostics lead medical advisor and professor Tom Jobling.

Cleo’s commercialisation efforts aim to lead to better outcomes for patients and save time and resources for the healthcare system. The clinical application of the ovarian cancer test would commence in 2025 upon granting of appropriate regulatory approvals, the article said.

To read the full article, click here.

.